시장보고서
상품코드
2130812

차세대 심장판막 임플란트 시장 분석 및 예측(-2035년) : 유형, 제품, 기술, 용도, 재료 유형, 디바이스, 프로세스, 최종사용자, 기능

Next Gen Heart Valve Implants Market Analysis and Forecast to 2035: Type, Product, Technology, Application, Material Type, Device, Process, End User, Functionality

발행일: | 리서치사: 구분자 Global Insight Services | 페이지 정보: 영문 350 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 4,750 금액 안내 화살표 ₩ 6,438,000
PDF & Excel (Site License) help
PDF, Excel 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다.
US $ 5,750 금액 안내 화살표 ₩ 7,794,000
PDF & Excel (Enterprise License) help
PDF, Excel 보고서를 동일 기업의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 6,750 금액 안내 화살표 ₩ 9,149,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 차세대 심장판막 임플란트 시장은 2025년 3억 990만 달러에서 2035년까지 7억 6,790만 달러로 성장하며, CAGR은 9.5%에 달할 것으로 예측됩니다. 차세대 심장 판막 임플란트 시장은 구조적 심장 질환, 고령화, 판막 질환 진단 건수 증가에 따른 막대하고 확대되고 있는 임상적 수요에 힘입어 성장하고 있습니다. 미국 질병통제예방센터(CDC)의 추정에 따르면 심장 판막 질환은 미국 성인의 약 2.5%에 영향을 미치고 있으며, 연간 2만 8,000명 이상의 사망이 이 질환에 기인하는 것으로 알려져 있습니다. 또한 임상 및 규제 측면의 변화에 따라 대상 환자층도 확대되고 있으며, 최근에는 경카테터 대동맥판막, 승모판막, 삼첨판막의 적용이 승인되었습니다. FDA의 승인은 최소 침습적 치환술, 밸브-인-밸브(Valve-in-Valve) 시술, 그리고 기존에는 수술에 적합하지 않다고 여겨졌던 환자를 위한 치료법 개발이 지속적으로 진행되고 있음을 보여줍니다.

차세대 심장 판막 임플란트에 사용되는 주요 재료 범주로는 금속, 폴리머, 조직, 세라믹이 있습니다. 코발트·크롬 및 관련 합금을 비롯한 금속 재료는 특히 경카테터 시스템에서 확장 가능한 판막 프레임에 구조적 강도와 지지력을 제공합니다. 고분자 소재는 유연성과 내구성을 조절할 수 있으며, 혈전 형성성을 낮춘 인공 판막의 설계를 가능하게 합니다. 일반적으로 소나 돼지 유래의 조직 기반 판막은 우수한 혈행동태적 특성을 갖추고 있으며, 생체 판막이나 경카테터 판막에 널리 채택되고 있습니다. 세라믹 소재는 높은 내구성, 화학적 안정성, 생체 적합성을 갖추고 있으나, 그 용도는 여전히 비교적 제한적입니다. 향후 성장은 내구성 향상, 석회화 감소, 더 소형화된 전달 프로파일의 실현, 환자 맞춤형 판막 설계를 가능하게 하는 소재에 유리하게 작용할 것으로 예상됩니다.

이 기기 부문은 판막 교체 전 과정을 지원하는 이식형 기기, 전달 시스템, 모니터링 기기로 구성되어 있습니다. 이식형 기기에는 대동맥판막, 승모판막, 삼첨판막, 폐동맥판막에 적용하기 위한 외과용 및 경카테터용 판막이 포함됩니다. 풍선 확장형 및 자가 확장형 카테터 플랫폼을 포함한 전달 시스템은 최소 침습적 이식을 가능하게 하며, 위치 결정, 혈관 접근 및 시술 제어성을 향상시키기 위해 점점 더 정교한 설계가 적용되고 있습니다. 모니터링 장치는 영상 진단, 혈행동태적 평가, 판막 기능 및 합병증 감시를 통해 이식 후 평가를 지원합니다. 경카테터 시술, 밸브-인-밸브(Valve-in-Valve) 치료, 그리고 수술 위험이 높은 환자에 대한 치료 선택지의 확대에 따라 통합된 기기 생태계에 대한 수요가 증가하고 있습니다.

지역별 개요

북미는 첨단인 심혈관 인프라, 확립된 구조적 심장 질환 프로그램, 전문 심장 센터, 그리고 광범위한 진단 완료 환자 기반을 바탕으로 차세대 심장 판막 이식 분야에서 확고한 입지를 유지하고 있습니다. 미국은 첨단 카테터 검사실, 경험이 풍부한 심장 의료진,보험 지급 제도, 그리고 탄탄한 의료기기 연구 역량을 바탕으로 이 지역의 주요 수요 거점으로 자리 잡고 있습니다. 규제 당국의 활동으로 제품 개발이 가속화되고 있으며, FDA 승인을 통해 대동맥판막, 승모판막, 삼첨판막 수술에 걸친 적응증이 확대되고 있습니다. 최근 승인된 경카테터 승모판 치환술 및 선천성 대동맥판 역류 치료는 임상 적용이 지속적으로 확대되고 있음을 보여줍니다. 제조사의 강력한 입지, 의사의 전문 지식, 임상 시험, 그리고 최소 침습 기술에 대한 투자가 시장 발전을 지속시키기 위한 유리한 생태계를 형성하고 있습니다.

유럽에서는 확립된 심장 의료 시스템, 경카테터 중재술의 활용 확대, 구조적 심장 질환에 대한 광범위한 임상 연구를 통해 큰 도입 가능성이 예상됩니다. 독일, 프랑스, 영국, 이탈리아 등 국가에는 복잡한 판막 교체술을 시행할 수 있는 전문적인 순환기 센터가 잘 갖춰져 있습니다. 임상 연구를 통해 판막 질환에 대한 이해는 계속해서 깊어지고 있으며, 고령층에서 이 질환의 유병률이 매우 높다는 것을 보여주는 증거도 확보되고 있습니다. 투자는 저침습 치료, 판막 내구성 향상, 첨단 영상 진단, 적응증 환자 선정으로 점점 더 집중되고 있습니다. 유럽의 제조사와 연구 기관들도 인공판막 소재 및 전달 기술의 혁신에 기여하고 있습니다. 경카테터 치료 경로의 확대와 최소 침습 시술에 대한 수요 증가가 이 지역의 지속적인 시장 성장을 지원할 것으로 전망됩니다.

주요 동향 및 촉진요인

보다 스마트하고 최소 침습적인 심장 판막 솔루션으로의 전환:

시장은 더 소형화된 삽입 프로파일, 판막 위치 결정 정밀도 향상, 판막엽 내구성 향상, 여러 심장 판막에 걸친 치료 범위 확대를 바탕으로, 저침습적 경카테터 심장 판막 치환술로 전환되고 있습니다. 개발은 밸브-인-밸브(Valve-in-Valve) 수술, 첨단 조직 기술, 기존에는 수술 대상이 아니었던 환자를 치료할 수 있는 플랫폼에 점점 더 초점을 맞추고 있습니다. 무증상 대동맥판막 협착증, 승모판 기능 부전, 삼첨판 질환으로의 적응증 확대로 인해 임상 적용 범위가 넓어지면서, 제조사들은 범용성이 더욱 높은 차세대 시스템 개발을 촉진하고 있습니다.

첨단 판막 치환 기술에 대한 수요 증가:

심장 판막 질환의 유병률 증가와 고령화 사회에서 효과적인 치료에 대한 임상적 수요가 증가함에 따라 이는 시장의 주요 성장 동력이 되고 있습니다. 심장 판막 질환은 심혈류량을 저해하고 심각한 합병증을 유발할 가능성이 있지만, 장기간 무증상 상태로 진행될 수 있으며, 진단은 여전히 어렵습니다. 저침습적 교체술의 선택지가 늘어남에 따라 수술 위험이 높은 환자들의 치료 접근성이 개선되고 있습니다. 경카테터 기술의 발전, 임상적 근거, 규제 당국의 승인은 카테터 기반 판막 교체 시스템으로 치료 가능한 환자군과 해부학적 상태의 범위를 확대함으로써, 의료진의 해당 기술 채택을 더욱 촉진하고 있습니다.

목차

제1장 개요

제2장 시장 하이라이트

제3장 시장 역학

제4장 부문 분석

제5장 지역별 분석

제6장 시장 전략

제7장 경쟁 정보

제8장 기업 개요

제9장 Global Insight Services 소개

KSA 26.09.29

The global Next Gen Heart Valve Implants Market is projected to grow from $309.9 Million in 2025 to $767.9 Million by 2035, at a compound annual growth rate (CAGR) of 9.5%. The next-generation heart valve implant market is supported by a substantial and expanding clinical need associated with structural heart disease, aging populations, and increasing diagnosis of valvular disorders. The CDC estimates that heart valve disease affects approximately 2.5% of U.S. adults, while more than 28,000 U.S. deaths annually are attributed to the condition. Clinical and regulatory activity is also broadening the addressable patient population, with recent approvals covering transcatheter aortic, mitral, and tricuspid valve applications. FDA approvals demonstrate continued development toward less invasive replacement, valve-in-valve procedures, and treatment of patients previously considered unsuitable for conventional surgery.

Metallic, polymeric, tissue, and ceramic materials form the primary material categories used in next-generation heart valve implants. Metallic materials, including cobalt-chromium and related alloys, provide structural strength and support for expandable valve frames, particularly in transcatheter systems. Polymeric materials offer opportunities for engineered leaflets with tunable flexibility, durability, and reduced thrombogenicity. Tissue-based valves, commonly derived from bovine or porcine sources, provide favorable hemodynamic characteristics and are widely incorporated into bioprosthetic and transcatheter valves. Ceramic materials offer high durability, chemical stability, and biocompatibility, although their application remains comparatively specialized. Growth is expected to favor materials that improve longevity, reduce calcification, enable smaller delivery profiles, and support patient-specific valve designs.

Market Segmentation
TypeMechanical Valves, Bioprosthetic Valves, Transcatheter Valves, Polymeric Valves, Others
ProductAortic Valve, Mitral Valve, Pulmonary Valve, Tricuspid Valve, Others
TechnologyTranscatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral Valve Repair (TMVR), Sutureless Valve Technology, 3D Printing, Others
ApplicationHeart Valve Disease, Congenital Heart Defects, Others
Material TypeMetal Alloys, Polymeric Materials, Biological Tissues, Ceramics, Others
DeviceValve Delivery Systems, Valve Repair Devices, Others
ProcessManufacturing, Quality Control, Sterilization, Packaging, Others
End UserHospitals, Ambulatory Surgical Centers, Specialty Clinics, Others
FunctionalityReplacement, Repair, Others

The device segment comprises implantable devices, delivery systems, and monitoring devices supporting the complete valve replacement pathway. Implantable devices include surgical and transcatheter valves designed for aortic, mitral, tricuspid, and pulmonary applications. Delivery systems, including balloon-expandable and self-expanding catheter platforms, facilitate minimally invasive implantation and are increasingly engineered for improved positioning, vascular access, and procedural control. Monitoring devices support post-implant assessment through imaging, hemodynamic evaluation, and surveillance of valve performance and complications. Expansion of transcatheter procedures, valve-in-valve interventions, and treatment options for patients at elevated surgical risk is strengthening demand for integrated device ecosystems.

Geographical Overview

North America maintains a strong position in next-generation heart valve implants due to advanced cardiovascular infrastructure, established structural-heart programs, specialized cardiac centers, and a large diagnosed patient base. The United States represents the principal regional demand center, supported by sophisticated catheterization laboratories, experienced heart teams, reimbursement mechanisms, and substantial medical-device research capabilities. Regulatory activity is accelerating product development, with FDA approvals expanding indications across aortic, mitral, and tricuspid procedures. Recent approvals for transcatheter mitral replacement and treatment of native aortic regurgitation demonstrate continued clinical expansion. Strong manufacturer presence, physician expertise, clinical trials, and investment in minimally invasive technologies provide a favorable ecosystem for continued market development.

Europe presents significant adoption potential through established cardiac-care systems, increasing utilization of transcatheter interventions, and extensive clinical research in structural heart disease. Countries including Germany, France, the United Kingdom, and Italy provide specialized cardiovascular centers capable of performing complex valve replacement procedures. Clinical research continues to strengthen understanding of valvular disease, including evidence identifying substantial disease prevalence among older populations. Investment is increasingly directed toward minimally invasive treatment, improved valve durability, advanced imaging, and patient selection. European manufacturers and research institutions also contribute to innovation in prosthetic materials and delivery technologies. Expansion of transcatheter treatment pathways and growing demand for less invasive procedures should support sustained regional market development.

Key Trends and Drivers

Shift Toward Smarter and Minimally Invasive Heart Valve Solutions:

The market is shifting toward minimally invasive and transcatheter heart valve replacement supported by smaller delivery profiles, improved valve positioning, enhanced leaflet durability, and expanded treatment across multiple cardiac valves. Development is increasingly focused on valve-in-valve procedures, advanced tissue technologies, and platforms capable of treating patients previously considered unsuitable for surgery. Regulatory expansion into asymptomatic aortic stenosis, mitral valve dysfunction, and tricuspid disease is broadening clinical applications and encouraging manufacturers to develop more versatile next-generation systems.

Rising Demand for Advanced Valve Replacement Technologies:

Rising prevalence of valvular heart disease and the growing clinical requirement for effective treatment among aging populations are major market drivers. Heart valve disease can impair cardiac blood flow and contribute to serious complications, while diagnosis remains challenging because disease can remain asymptomatic for extended periods. Increasing availability of minimally invasive replacement procedures is improving treatment accessibility for patients with elevated surgical risk. Advances in transcatheter technology, clinical evidence, and regulatory approvals are further supporting physician adoption by expanding the range of patients and anatomical conditions that can be treated with catheter-based valve systems.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Material Type
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Mechanical Valves
    • 4.1.2 Bioprosthetic Valves
    • 4.1.3 Transcatheter Valves
    • 4.1.4 Polymeric Valves
    • 4.1.5 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Aortic Valve
    • 4.2.2 Mitral Valve
    • 4.2.3 Pulmonary Valve
    • 4.2.4 Tricuspid Valve
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Transcatheter Aortic Valve Replacement (TAVR)
    • 4.3.2 Transcatheter Mitral Valve Repair (TMVR)
    • 4.3.3 Sutureless Valve Technology
    • 4.3.4 3D Printing
    • 4.3.5 Others
  • 4.4 Market Size & Forecast by Material Type (2020-2035)
    • 4.4.1 Metal Alloys
    • 4.4.2 Polymeric Materials
    • 4.4.3 Biological Tissues
    • 4.4.4 Ceramics
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Heart Valve Disease
    • 4.5.2 Congenital Heart Defects
    • 4.5.3 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Ambulatory Surgical Centers
    • 4.6.3 Specialty Clinics
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Manufacturing
    • 4.7.2 Quality Control
    • 4.7.3 Sterilization
    • 4.7.4 Packaging
    • 4.7.5 Others
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Valve Delivery Systems
    • 4.8.2 Valve Repair Devices
    • 4.8.3 Others
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Replacement
    • 4.9.2 Repair
    • 4.9.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Material Type
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Device
      • 5.2.1.9 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Material Type
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Device
      • 5.2.2.9 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Material Type
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Device
      • 5.2.3.9 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Material Type
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Device
      • 5.3.1.9 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Material Type
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Device
      • 5.3.2.9 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Material Type
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Device
      • 5.3.3.9 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Material Type
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Device
      • 5.4.1.9 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Material Type
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Device
      • 5.4.2.9 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Material Type
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Device
      • 5.4.3.9 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Material Type
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Device
      • 5.4.4.9 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Material Type
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Device
      • 5.4.5.9 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Material Type
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Device
      • 5.4.6.9 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Material Type
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Device
      • 5.4.7.9 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Material Type
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Device
      • 5.5.1.9 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Material Type
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Device
      • 5.5.2.9 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Material Type
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Device
      • 5.5.3.9 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Material Type
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Device
      • 5.5.4.9 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Material Type
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Device
      • 5.5.5.9 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Material Type
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Device
      • 5.5.6.9 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Material Type
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Device
      • 5.6.1.9 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Material Type
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Device
      • 5.6.2.9 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Material Type
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Device
      • 5.6.3.9 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Material Type
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Device
      • 5.6.4.9 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Material Type
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Device
      • 5.6.5.9 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Edwards Lifesciences
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Medtronic
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Abbott Laboratories
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Boston Scientific
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 LivaNova
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 CryoLife
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 JenaValve Technology
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Micro Interventional Devices
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 TTK Healthcare
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Colibri Heart Valve
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Biotronik
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 St Jude Medical
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Sorin Group
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Braile Biomedica
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Meril Life Sciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Transcatheter Technologies
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Heart Leaflet Technologies
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Valcare Medical
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Venus Medtech
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Peijia Medical
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기